South Korean beauty manufacturer Biovijou (489460) is accelerating its entry into the extracellular matrix (ECM) skin booster market, securing a new growth driver through an exclusive global distribution agreement. The move diversifies its revenue stream beyond China-focused exports and positions the company to capture demand in the fast-growing ECM aesthetic segment, a development relevant for overseas buyers tracking injectable and skin booster supply chains.
Market signal
Biovijou has secured exclusive global distribution rights for 'Cellivion Lindsey', an ECM-based skin booster developed in collaboration with medical tech firm Orthotech. The product targets the rapidly expanding ECM skin booster market, currently dominated by L&C Bio's 'Rituo' and Hans Biomed's 'Celldiem'. Biovijou's entry as a latecomer leverages aggressive marketing and an existing dermatology clinic network.
Company profile and production capacity
Biovijou primarily manufactures cosmetics, fillers, and skin boosters, with an annual production capacity of 2.64 million units. A second factory expansion is planned to boost capacity to 8.64 million units. Overseas sales accounted for 85% of first-quarter revenue, with China representing 70% of total 2025 sales. The company's parent, Cheongdam Global, provides a competitive local distribution network in China.
US market expansion
Biovijou has begun targeting the US market, though first-quarter US sales were only KRW 600 million (approx. USD 450,000). The company plans to expand Western marketing efforts from the second half of 2026 through pop-up events and other initiatives, signaling growing interest in North American aesthetic device and injectable distribution channels.
Pricing and sales strategy
Biovijou started domestic clinic sales in March 2026, pricing its ECM skin booster approximately 10% lower than competing products. Shin Young Securities estimates 2026 revenue of KRW 38 billion (approx. USD 28.5 million) with a 30% operating margin, including KRW 5 billion (approx. USD 3.75 million) from ECM product sales. The domestic ECM skin booster market is described as having demand exceeding supply, creating a favorable entry environment.
What buyers should watch
For overseas importers and clinic buyers, Biovijou's ECM skin booster rollout warrants monitoring. Key indicators include the pace of hospital adoption, real-world treatment reviews, and expansion into Western markets. The company's existing filler and skin booster manufacturing expertise, combined with aggressive pricing, could make it a competitive supplier for clinics seeking cost-effective ECM-based aesthetic solutions.
Source: Read the original report | Published: June 16, 2026